Revenue decreased 3.2%
Revenue changed -3.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$119.9M→$116.1M3 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed -3.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Research & development changed +29.3% from the comparable as-filed period.
Gross profit changed -6.2% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.